News Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq Other stock markets 02:00:01 07/05/2024 am IST			5-day change	1st Jan Change
26.33 ^USD	-0.45%		+6.60%	+190.94%

04/04	Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	MT
04/04	Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avidity Biosciences : April 2024 Corporate Presentation	01/05	PU
Avidity Biosciences : (5.7 MB)	29/04	PU
Avidity Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	23/04	AQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	23/04	PR
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	04/04	MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	04/04	MT
Avidity Biosciences to Participate in Upcoming Investor Conferences	27/03	PR
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/03	PR
Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding	19/03	CI
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	16/03	MT
Cantor Fitzgerald Starts Avidity Biosciences With Overweight Rating, $60 Price Target	14/03	MT
Transcript : Avidity Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:05 PM	13/03
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	13/03	MT
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	06/03	MT
Chardan Ups Price Target on Avidity Biosciences to $33 From $23 on Efficacy, Safety DM1 Data, Keeps Buy Rating	05/03	MT
Transcript : Avidity Biosciences, Inc. - Shareholder/Analyst Call	04/03
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial	04/03	PR
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial	04/03	CI
North American Morning Briefing : Stock Futures -2-	04/03	DJ
Avidity Biosciences Honors Rare Disease Day	01/03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Summary

Filters